RecruitingPhase 4NCT05390515
Psoriatic Immune Response to Tildrakizumab
Sponsor
University of California, San Francisco
Enrollment
10 participants
Start Date
Sep 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Tildrakizumab Prefilled Syringe for people with psoriasis vulgaris. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTildrakizumab Prefilled Syringe
IL-23 inhibitor
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05390515
Related Trials
Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT058586451 location
Proactive TDM Versus Standard Use of Biologics in Psoriasis
NCT0639810615 locations
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
NCT074261201 location
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
NCT073208721 location
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis
NCT049502181 location